(MBRX) Moleculin Biotech, Inc. Business Model Canvas Research

Hospitals and principal investigators are the engine for Moleculin Biotech, Inc.’s oncology and virology studies: they enroll patients, give doses, and collect the data that drives each trial. In 2025, with no commercial revenue, execution speed still depends on site access and investigator support.

• Enrollment depends on site activation
• Dosing and data collection happen on-site
• Trial pace is set by investigators

Moleculin Biotech, Inc. relies on CRO and manufacturing vendors to run studies, manage monitoring and logistics, and supply clinical-grade materials, which helps avoid building a large in-house trial and production base. In 2025, CROs supported a global clinical research market above $70 billion, showing how much biotech firms depend on outsourced execution.

• Supports trials, monitoring, and logistics
• Provides clinical-grade supply
• Reduces fixed infrastructure needs

Moleculin Biotech, Inc. must keep FDA and IRB reviews moving for its clinical-stage studies, so it can file protocol changes, safety updates, and amendments on time. These submissions keep trials active and compliant, and any delay can slow patient dosing, site activation, and data readouts.

• Manage FDA and IRB filings
• Report safety events fast
• Track protocol amendments
• Keep trials compliant

Moleculin Biotech, Inc. manages licensing, collaborations, and patent assets around its lead compounds and platform technologies, keeping control over IP that can support future deals and cash monetization. This work helps protect the pipeline and the company’s partner value.

• Protects lead compounds with patents
• Supports licensing and partnerships
• Creates future monetization paths

Moleculin Biotech, Inc. depends on its clinical and partnership network, especially MD Anderson and WPD Pharmaceuticals, to extend trial design, research depth, and execution support. For a small clinical-stage company, these intangible assets matter more than owned labs: they reduce development burden across a pipeline that, in FY2024, still operated with limited cash and relied on outside expertise.

• MD Anderson adds clinical credibility
• WPD supports execution and research
• Outsourced network lowers fixed costs

Moleculin Biotech, Inc. is based in Houston, Texas, and its small core team runs strategy, development, finance, and partnering from that hub. In FY2025, Company reported $0 revenue, which fits a lean headquarters model typical for a clinical-stage biotech.

• Houston, Texas headquarters
• Core team handles key functions
• FY2025 revenue: $0
• Lean biotech HQ structure

WP1220 is a topical CTCL candidate built for skin delivery, which can make treatment easier to use than systemic options for a rare, hard-to-treat cancer. In CTCL, where disease often stays on the skin, a local route can better match the site of action and support differentiated positioning in a small patient pool.

• Topical use fits skin-limited CTCL
• May improve patient usability
• Offers a distinct rare-cancer route

Moleculin Biotech, Inc. uses WP1122 to target glioblastoma multiforme and COVID-19, giving the program value across cancer and antiviral use. That matters in GBM, where median survival is about 15 months and 5-year survival is roughly 7%, so one chemistry platform can serve two high-unmet-need markets.

• WP1122 spans oncology and antiviral uses.
• GBM has very poor survival rates.
• One platform supports multiple shots.

Licensing and BD engagement at Moleculin Biotech, Inc. is a high-touch relationship: partners expect clean data rooms, clear trial data, and fast diligence support. That makes structured negotiation core to future monetization, since each deal can shape upfront fees, milestones, and royalties.

• Data rooms must stay diligence-ready
• Deal talks need fast, documented support
• Licensing is key to future cash flow

Moleculin Biotech, Inc. uses active investor relations because trial readouts, financing, and milestone news can move the share price fast. Public disclosure keeps shareholders informed and helps the Company stay visible to the market.

• Trial updates
• Financing news
• Milestone disclosures
• Supports capital access

That communication is key for a biotech that depends on outside funding.

Moleculin Biotech, Inc. uses SEC filings and investor relations updates to broadcast trial milestones, funding moves, and risk changes. As a public clinical-stage company, these channels reach both shareholders and new capital providers through Forms 10-K, 10-Q, 8-K, earnings releases, and webcast updates.

• Shares clinical milestones fast
• Reaches investors and lenders
• Supports fundraising credibility

Business development outreach at Moleculin Biotech, Inc. is handled directly with biopharma and research groups, making it the main path for licensing and collaboration talks. This channel can turn clinical and preclinical data into non-dilutive value, which matters when development spend remains high and partners can fund next steps.

• Direct partner talks
• Licensing and collaboration deals
• Converts data into non-dilutive value

CTCL patients are a small, high-need segment: cutaneous T-cell lymphoma is a rare non-Hodgkin lymphoma that starts in the skin, so local treatment can fit well. WP1220 is aimed at this dermatologic oncology niche, where skin-directed therapy can help limit whole-body exposure.

• Rare, skin-first cancer segment
• Fits local treatment use
• WP1220 targets dermatologic oncology

This makes the customer group tightly defined and clinically specific, which can support focused adoption if efficacy and tolerability are proven in CTCL.

Biopharma and research partners are a core customer segment for Moleculin Biotech, Inc. In 2025, these licensing and collaboration counterparties can include pharmaceutical companies, academic centers, and development partners that help fund studies or push assets through preclinical and clinical work.

• Pharma can license and co-develop assets
• Academia can add trial and science capacity
• Partners can fund R&D and de-risk programs

That matters most for a pre-revenue biotech, where each partner can speed data generation and reduce cash burn.

Regulatory and compliance costs stay on at Moleculin Biotech, Inc. through the full program life: IND maintenance, safety reporting, and legal support are required, and public-company filing, audit, and exchange-listing work adds more expense. These are recurring cash drains, not one-time items.

• IND updates and safety reports
• Legal and regulatory counsel
• Public-company filing and audit costs
• Ongoing through development

Moleculin Biotech, Inc. spends on patent maintenance, licensing work, and collaborator management to protect and monetize its asset base. FY2025 filings show a pre-revenue profile, so these IP and partnership costs sit alongside due diligence and contract administration as core overhead, not optional extras.

• Patent fees protect pipeline value
• Licensing and partner work add overhead
• Contract checks support monetization

If Moleculin Biotech, Inc.’s partnered programs reach market, royalties on future sales can add cash upside without building a full sales force or manufacturing network. This is a standard late-stage biotech model: the partner funds commercialization, and Moleculin Biotech, Inc. keeps a slice of net sales.

• Upside from partner-led launches
• No full commercial buildout needed
• Royalty income scales with sales

Grants and research funding can give Moleculin Biotech, Inc. non-dilutive cash from NIH, BARDA, or state programs, helping pay for early R&D without issuing new shares. For rare or high-need cancers, NIH SBIR awards can reach $2.0 million to $2.5 million, which can offset preclinical and IND-enabling work.

• Non-dilutive funding reduces share dilution.
• Best fit for rare, high-need indications.
• Covers early research cost gaps.